Marta Calvo - Concepedia

Author

Marta Calvo

Hospital Universitario Puerta de Hierro Majadahonda ORCID

Also Known As

Angel Muñoz-Herrera, Calvo, Marta, José Manuel Benítez, M Calvo, M Calvo Moya, M I Calvo Moya, M Moya, M. CALVO, M. Calvo, M. Calvo Moya

243

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Puerta de Hierro Majadahonda Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas Hospital Clínico San Carlos Hospital Universitario de La Princesa Hospital Clínic de Barcelona

About

Marta Calvo is an author at Hospital Universitario Puerta de Hierro Majadahonda specializing in medicine, gastroenterology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	517
2	Public Health	3	3	103
3	Health Sciences	1	1	18
4	Social Sciences	1	1	36
5	Emergency Medicine	1	1	34

Marta Calvo

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse Javier P. Gisbert, Fernando Bermejo, Jose-Lázaro Pérez-Calle, Inflammatory Bowel Diseases	2009	311
Safety of Thiopurines and Anti-TNF-α Drugs During Pregnancy in Patients With Inflammatory Bowel Disease María José Casanova, María Chaparro, Eugeni Domènech, The American Journal of Gastroenterology	2013	232
Prevalence of Malnutrition and Nutritional Characteristics of Patients With Inflammatory Bowel Disease María José Casanova, María Chaparro, Begoña Molina, Journal of Crohn s and Colitis	2017	180
Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine‐induced pancreatitis Fernando Bermejo, Antonio López–Sanromán, Carlos Taxonera, Alimentary Pharmacology & Therapeutics	2008	134
Epidemiological risk factors in microscopic colitis: a prospective case-control study. Fernando Fernández‐Bañares, Monia R. de Sousa, Antonio Salas, PubMed	2013	132
Randomized trial comparing pegylated interferon α‐2b versus pegylated interferon α‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients† Montserrat Laguno, Javier Murillas, Sergio Veloso, Hepatology	2008	111
Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients Yago González‐Lama, Fernando Bermejo, Antonio López–Sanromán, Alimentary Pharmacology & Therapeutics	2011	86
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis Carlos Taxonera, Cristina Rodríguez, Federico Bertoletti, Inflammatory Bowel Diseases	2017	80
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry María Chaparro, A Garre, Marisa Iborra, Journal of Crohn s and Colitis	2021	79
Characteristics and Treatment of Pyoderma Gangrenosum in Inflammatory Bowel Disease Federico Argüelles‐Arias, Luisa Castro-Laria, Triana Lobatón, Digestive Diseases and Sciences GastroenterologyPathologyClinical GastroenterologyUlcerative ColitisMedicine	2013	77

Page 1